Literature DB >> 9466538

Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults.

A R Falsey1, E E Walsh.   

Abstract

The relationship of serum antibody to respiratory syncytial virus (RSV) and risk of RSV infection was prospectively evaluated in frail elderly persons. Baseline blood samples from 22 subjects who developed symptomatic RSV infection during the 26-month study and from 22 control subjects who did not become infected with RSV were compared. The mean serum IgG titer to RSV fusion protein was significantly lower in the RSV-infected group than in the controls (15.4 +/- 1.6 vs. 16.4 +/- 1.8, P = .05), as were the neutralizing titers to group A RSV (12.4 +/- 2.2 vs. 14.2 +/- 2.2, P = .008) and group B virus (9.1 +/- 2.1, vs. 10.3 +/- 1.5, P = .01). These results suggest that older adults with low titers of serum neutralizing antibody may be at greater risk of developing symptomatic RSV infection than those who have high antibody titers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466538     DOI: 10.1086/517376

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  61 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Effects of aging on the adaptive immune response to respiratory virus infections.

Authors:  Ross B Fulton; Steven M Varga
Journal:  Aging health       Date:  2009-12-01

Review 3.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

Review 4.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

Review 5.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

6.  Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.

Authors:  Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

7.  Respiratory syncytial virus vaccine: Is it coming?

Authors:  Valérie Sales; Elaine El Wang
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

8.  Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.

Authors:  Young-Man Kwon; Youri Lee; Ki Hye Kim; Yu Jin Jung; Zhuo Li; Subbiah Jeeva; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-09-18       Impact factor: 3.641

Review 9.  Current research on respiratory viral infections: Fourth International Symposium.

Authors:  Michael G Ison; John Mills; Peter Openshaw; Maria Zambon; Albert Osterhaus; Frederick Hayden
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

Review 10.  Low zinc status: a new risk factor for pneumonia in the elderly?

Authors:  Junaidah B Barnett; Davidson H Hamer; Simin N Meydani
Journal:  Nutr Rev       Date:  2010-01       Impact factor: 7.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.